February 1, 2025
Bavarian Nordic – Completion of Share Buy-Back Program
COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced…
Pharmaceuticals, Biotechnology and Life Sciences
COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced…
CORRECTION – Financial agenda for 2025 Villepinte, 13 janvier 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and…
Multilingual upgrade will make INBS’ Drug Screening System accessible to over 4 billion users worldwide, including users across the Americas,…
CHAPEL HILL, N.C., Jan. 31, 2025 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a…
US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex…
ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval…
NewGen’s ordinary shares to begin trading on a split-adjusted basis on February 11, 2025BANGKOK, Jan. 31, 2025 (GLOBE NEWSWIRE) —…
Media Release Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung…
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing,…
REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company…